|
|
|
|
| LEADER |
01000naa a22002652 4500 |
| 001 |
NLM254970575 |
| 003 |
DE-627 |
| 005 |
20231224173519.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231224s2016 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.clim.2015.11.007
|2 doi
|
| 028 |
5 |
2 |
|a pubmed24n0849.xml
|
| 035 |
|
|
|a (DE-627)NLM254970575
|
| 035 |
|
|
|a (NLM)26604012
|
| 035 |
|
|
|a (PII)S1521-6616(15)30064-4
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Regna, Nicole L
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Specific HDAC6 inhibition by ACY-738 reduces SLE pathogenesis in NZB/W mice
|
| 264 |
|
1 |
|c 2016
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Completed 05.05.2016
|
| 500 |
|
|
|a Date Revised 16.11.2017
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status MEDLINE
|
| 520 |
|
|
|a Copyright © 2015 The Authors. Published by Elsevier Inc. All rights reserved.
|
| 520 |
|
|
|a We sought to determine if a selective HDAC6 inhibitor (ACY-738) decreases disease in NZB/W mice. From 22 to 38weeks-of-age, mice were injected intraperitoneally with 5 or 20mg/kg of ACY-738, or vehicle control. Body weight and proteinuria were measured every 2weeks, while sera anti-dsDNA, Ig isotypes, and cytokine levels were measured every 4weeks. Kidney disease was determined by evaluation of sera, urine, immune complex deposition, and renal pathology. Flow cytometric analysis assessed thymic, splenic, bone marrow, and peripheral lymphocyte differentiation patterns. Our results showed HDAC6 inhibition decreased SLE disease by inhibiting immune complex-mediated glomerulonephritis, sera anti-dsDNA levels, and inflammatory cytokine production and increasing splenic Treg cells. Inhibition of HDAC6 increased the percentage of cells in the early-stage developmental fractions of both pro- and pre-B cells. These results suggest that specific HDAC6 inhibition may be able to decrease SLE disease by altering aberrant T and B cell differentiation
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Research Support, Non-U.S. Gov't
|
| 650 |
|
4 |
|a B cells
|
| 650 |
|
4 |
|a HDAC
|
| 650 |
|
4 |
|a Systemic lupus erythematosus
|
| 650 |
|
4 |
|a T cells
|
| 650 |
|
7 |
|a Enzyme Inhibitors
|2 NLM
|
| 650 |
|
7 |
|a Hydroxamic Acids
|2 NLM
|
| 650 |
|
7 |
|a N-hydroxy-2-(1-phenylcycloproylamino)pyrimidine-5-carboxamide
|2 NLM
|
| 650 |
|
7 |
|a Pyrimidines
|2 NLM
|
| 650 |
|
7 |
|a Hdac6 protein, mouse
|2 NLM
|
| 650 |
|
7 |
|a EC 3.5.1.98
|2 NLM
|
| 650 |
|
7 |
|a Histone Deacetylase 6
|2 NLM
|
| 650 |
|
7 |
|a EC 3.5.1.98
|2 NLM
|
| 650 |
|
7 |
|a Histone Deacetylases
|2 NLM
|
| 650 |
|
7 |
|a EC 3.5.1.98
|2 NLM
|
| 700 |
1 |
|
|a Vieson, Miranda D
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Luo, Xin M
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chafin, Cristen B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Puthiyaveetil, Abdul Gafoor
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Hammond, Sarah E
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Caudell, David L
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jarpe, Matthew B
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Reilly, Christopher M
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Clinical immunology (Orlando, Fla.)
|d 1999
|g 162(2016) vom: 25. Jan., Seite 58-73
|w (DE-627)NLM098196855
|x 1521-7035
|7 nnns
|
| 773 |
1 |
8 |
|g volume:162
|g year:2016
|g day:25
|g month:01
|g pages:58-73
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.clim.2015.11.007
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_11
|
| 912 |
|
|
|a GBV_ILN_24
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 162
|j 2016
|b 25
|c 01
|h 58-73
|